Neil A. Klompas - Mar 10, 2022 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chief Operating Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Mar 10, 2022
Transactions value $
-$20,496
Form type
4
Date filed
3/11/2022, 08:00 PM
Previous filing
Jan 7, 2022
Next filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Shares Options Exercise $0 +2.5K +22.63% $0.00 13.5K Mar 10, 2022 Direct F1
transaction ZYME Common Shares Options Exercise $0 +2.71K +19.99% $0.00 16.3K Mar 10, 2022 Direct F2
transaction ZYME Common Shares Sale -$20.5K -2.98K -18.33% $6.88* 13.3K Mar 10, 2022 Direct F3, F4
holding ZYME Common Shares 700 Mar 10, 2022 Held by spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -2.5K -50% $0.00 2.5K Mar 10, 2022 Common Shares 2.5K Direct F5, F6
transaction ZYME Restricted Stock Unit Options Exercise $0 -2.71K -33.33% $0.00 5.42K Mar 10, 2022 Common Shares 2.71K Direct F5, F7
transaction ZYME Stock Option (Right to Buy) Award $0 +200K $0.00 200K Mar 10, 2022 Common Shares 200K $7.00 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2 Represents common shares issued upon vesting of one third of the RSUs granted on March 10, 2021.
F3 Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (each, a "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. The Reporting Person is subject to a Lock Up Agreement that expires on March 27, 2022. The sale of shares is a permissible exemption under the terms of the Lock Up Agreement. The remaining shares held by the Reporting Person following this sale remain subject to the terms of the Lock Up Agreement.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.83 to $6.97, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F6 The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F7 The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022.
F8 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.